Obtained approval from the Hong Kong Stock Exchange to officially remove the "B" label from the stock code starting April 23, 2021
In July 2021, the first subject was dosed in a Phase I clinical trial completed in China
In October 2025, the SLRU antibody clinical trial in the perioperative period for gastric cancer reached the primary endpoint EFS, supporting early market launch